Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus + Genotype 1 Infected Subjects.

Trial Profile

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus + Genotype 1 Infected Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Dasabuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 26 Apr 2009 Pharmacokinetic results reported at The International Liver Congress 2009.
    • 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Planned number of patients changed from 116 to 133 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top